[
  {
    "ts": "2026-01-20T00:11:01+00:00",
    "headline": "Looking At The Narrative For Alector (ALEC) After Latozinemab Setback And Cost Cuts",
    "summary": "The fair value estimate for Alector has shifted slightly, moving from 2.05 to 2.10, while the discount rate has also adjusted from 7.54% to 7.39%, even as the revenue growth assumption remains anchored to about a 50.08% decline. This reflects a recalibrated view after mixed Street research, where cautious ratings, the failed latozinemab Phase 3 trial, and a pipeline reset sit alongside cost cuts and remaining pipeline options that some investors still factor into their thinking. Continue with...",
    "url": "https://finance.yahoo.com/news/looking-narrative-alector-alec-latozinemab-001101574.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "eab01199-304a-3201-a0ca-094c2115d79d",
      "content": {
        "id": "eab01199-304a-3201-a0ca-094c2115d79d",
        "contentType": "STORY",
        "title": "Looking At The Narrative For Alector (ALEC) After Latozinemab Setback And Cost Cuts",
        "description": "",
        "summary": "The fair value estimate for Alector has shifted slightly, moving from 2.05 to 2.10, while the discount rate has also adjusted from 7.54% to 7.39%, even as the revenue growth assumption remains anchored to about a 50.08% decline. This reflects a recalibrated view after mixed Street research, where cautious ratings, the failed latozinemab Phase 3 trial, and a pipeline reset sit alongside cost cuts and remaining pipeline options that some investors still factor into their thinking. Continue with...",
        "pubDate": "2026-01-20T00:11:01Z",
        "displayTime": "2026-01-20T00:11:01Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/I2k3PKJsWIEX9xgEQz8JwQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tmSjpFKmBAT61w1lG5.BLQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/looking-narrative-alector-alec-latozinemab-001101574.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/looking-narrative-alector-alec-latozinemab-001101574.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ALEC"
            },
            {
              "symbol": "MS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]